Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients with Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 2, p. s403, 2024. DOI: 10.25251/skin.8.supp.403. Disponível em: https://skin.dermsquared.com/skin/article/view/2731. Acesso em: 18 apr. 2026.